Like countless companies in the Boston area, Akili is in the midst of the long, drawn-out and a little nerve-wracking process of submitting its lead product to the FDA for approval. But unlike the challenges facing other pharma giants and biotech startups, Akili’s product is not a pill, an injection, a salve or a balm. Instead, Akili is asking the FDA to approve a video game.